Cardiovascular effect and simultaneous pharmacokinetic and pharmacodynamic modeling of pimobendan in healthy normal subjects

Kai Min Chu, Oliver Yoa Pu Hu, Shyh Ming Shieh

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Pimobendan is a new inotropic agent with vasodilator properties. We have reported the pharmacokinetics of enantiomers of pimobendan in healthy humans. The present report focuses on the pharmacodynamic effect of pimobendan and a simultaneous pharmacokinetic-pharmacodynamic modeling. Eight normal healthy volunteers were studied with oral administration of 7.5 mg and i.v. administration of 5 mg of racemic pimobendan. Concentrations of enantiomers of pimobendan were determined by high performance liquid chromatography. Cardiovascular effects of pimobendan were evaluated by echocardiography. Oral pimobendan significantly reduced 29.0% and 16.5% of the left ventricle end- systolic dimension (LVESD) and end-diastolic dimension, respectively. The mean velocity of circumferential fiber shortening, ejection fraction, and fractional shortening significantly increased 105.9%, 29.8%, and 46% from their baseline values, respectively. The cardiovascular effects of i.v. pimobendan were similar but to a lesser extent. Plots of effect versus plasma concentration (C(p)) showed counterclockwise hysteresis loops. A hypothetical effect compartment was established and incorporated into a sigmoid E(max) model to describe the time courses of C(p)S of pimobendan and effects on LVESD. The maximal changes (E(max)) in LVESD would be 2.60 ± 0.51 cm and 2.30 ± 0.13 cm as estimated from plasma data of (+)- and (-)-pimobendan, respectively. The estimated effect-site concentrations corresponding with 50% of the maximal effect (C(e50)) were 6.54 ± 1.35 and 6.64 ± 1.35 ng/ml for (+)- and (-)-pimobendan, respectively. A simultaneous pharmacokinetic- pharmacodynamic model could be established to suppress the hysteresis loop and to predict the pharmacological effect based on C(p).

Original languageEnglish
Pages (from-to)701-709
Number of pages9
JournalDrug Metabolism and Disposition
Volume27
Issue number6
Publication statusPublished - Jun 9 1999
Externally publishedYes

Fingerprint

Healthy Volunteers
Pharmacokinetics
Heart Ventricles
pimobendan
Sigmoid Colon
Vasodilator Agents
Oral Administration
Echocardiography
High Pressure Liquid Chromatography
Pharmacology

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Cardiovascular effect and simultaneous pharmacokinetic and pharmacodynamic modeling of pimobendan in healthy normal subjects. / Chu, Kai Min; Hu, Oliver Yoa Pu; Shieh, Shyh Ming.

In: Drug Metabolism and Disposition, Vol. 27, No. 6, 09.06.1999, p. 701-709.

Research output: Contribution to journalArticle

@article{9a0dcefdcd20409ca490eeca6d7e858b,
title = "Cardiovascular effect and simultaneous pharmacokinetic and pharmacodynamic modeling of pimobendan in healthy normal subjects",
abstract = "Pimobendan is a new inotropic agent with vasodilator properties. We have reported the pharmacokinetics of enantiomers of pimobendan in healthy humans. The present report focuses on the pharmacodynamic effect of pimobendan and a simultaneous pharmacokinetic-pharmacodynamic modeling. Eight normal healthy volunteers were studied with oral administration of 7.5 mg and i.v. administration of 5 mg of racemic pimobendan. Concentrations of enantiomers of pimobendan were determined by high performance liquid chromatography. Cardiovascular effects of pimobendan were evaluated by echocardiography. Oral pimobendan significantly reduced 29.0{\%} and 16.5{\%} of the left ventricle end- systolic dimension (LVESD) and end-diastolic dimension, respectively. The mean velocity of circumferential fiber shortening, ejection fraction, and fractional shortening significantly increased 105.9{\%}, 29.8{\%}, and 46{\%} from their baseline values, respectively. The cardiovascular effects of i.v. pimobendan were similar but to a lesser extent. Plots of effect versus plasma concentration (C(p)) showed counterclockwise hysteresis loops. A hypothetical effect compartment was established and incorporated into a sigmoid E(max) model to describe the time courses of C(p)S of pimobendan and effects on LVESD. The maximal changes (E(max)) in LVESD would be 2.60 ± 0.51 cm and 2.30 ± 0.13 cm as estimated from plasma data of (+)- and (-)-pimobendan, respectively. The estimated effect-site concentrations corresponding with 50{\%} of the maximal effect (C(e50)) were 6.54 ± 1.35 and 6.64 ± 1.35 ng/ml for (+)- and (-)-pimobendan, respectively. A simultaneous pharmacokinetic- pharmacodynamic model could be established to suppress the hysteresis loop and to predict the pharmacological effect based on C(p).",
author = "Chu, {Kai Min} and Hu, {Oliver Yoa Pu} and Shieh, {Shyh Ming}",
year = "1999",
month = "6",
day = "9",
language = "English",
volume = "27",
pages = "701--709",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "6",

}

TY - JOUR

T1 - Cardiovascular effect and simultaneous pharmacokinetic and pharmacodynamic modeling of pimobendan in healthy normal subjects

AU - Chu, Kai Min

AU - Hu, Oliver Yoa Pu

AU - Shieh, Shyh Ming

PY - 1999/6/9

Y1 - 1999/6/9

N2 - Pimobendan is a new inotropic agent with vasodilator properties. We have reported the pharmacokinetics of enantiomers of pimobendan in healthy humans. The present report focuses on the pharmacodynamic effect of pimobendan and a simultaneous pharmacokinetic-pharmacodynamic modeling. Eight normal healthy volunteers were studied with oral administration of 7.5 mg and i.v. administration of 5 mg of racemic pimobendan. Concentrations of enantiomers of pimobendan were determined by high performance liquid chromatography. Cardiovascular effects of pimobendan were evaluated by echocardiography. Oral pimobendan significantly reduced 29.0% and 16.5% of the left ventricle end- systolic dimension (LVESD) and end-diastolic dimension, respectively. The mean velocity of circumferential fiber shortening, ejection fraction, and fractional shortening significantly increased 105.9%, 29.8%, and 46% from their baseline values, respectively. The cardiovascular effects of i.v. pimobendan were similar but to a lesser extent. Plots of effect versus plasma concentration (C(p)) showed counterclockwise hysteresis loops. A hypothetical effect compartment was established and incorporated into a sigmoid E(max) model to describe the time courses of C(p)S of pimobendan and effects on LVESD. The maximal changes (E(max)) in LVESD would be 2.60 ± 0.51 cm and 2.30 ± 0.13 cm as estimated from plasma data of (+)- and (-)-pimobendan, respectively. The estimated effect-site concentrations corresponding with 50% of the maximal effect (C(e50)) were 6.54 ± 1.35 and 6.64 ± 1.35 ng/ml for (+)- and (-)-pimobendan, respectively. A simultaneous pharmacokinetic- pharmacodynamic model could be established to suppress the hysteresis loop and to predict the pharmacological effect based on C(p).

AB - Pimobendan is a new inotropic agent with vasodilator properties. We have reported the pharmacokinetics of enantiomers of pimobendan in healthy humans. The present report focuses on the pharmacodynamic effect of pimobendan and a simultaneous pharmacokinetic-pharmacodynamic modeling. Eight normal healthy volunteers were studied with oral administration of 7.5 mg and i.v. administration of 5 mg of racemic pimobendan. Concentrations of enantiomers of pimobendan were determined by high performance liquid chromatography. Cardiovascular effects of pimobendan were evaluated by echocardiography. Oral pimobendan significantly reduced 29.0% and 16.5% of the left ventricle end- systolic dimension (LVESD) and end-diastolic dimension, respectively. The mean velocity of circumferential fiber shortening, ejection fraction, and fractional shortening significantly increased 105.9%, 29.8%, and 46% from their baseline values, respectively. The cardiovascular effects of i.v. pimobendan were similar but to a lesser extent. Plots of effect versus plasma concentration (C(p)) showed counterclockwise hysteresis loops. A hypothetical effect compartment was established and incorporated into a sigmoid E(max) model to describe the time courses of C(p)S of pimobendan and effects on LVESD. The maximal changes (E(max)) in LVESD would be 2.60 ± 0.51 cm and 2.30 ± 0.13 cm as estimated from plasma data of (+)- and (-)-pimobendan, respectively. The estimated effect-site concentrations corresponding with 50% of the maximal effect (C(e50)) were 6.54 ± 1.35 and 6.64 ± 1.35 ng/ml for (+)- and (-)-pimobendan, respectively. A simultaneous pharmacokinetic- pharmacodynamic model could be established to suppress the hysteresis loop and to predict the pharmacological effect based on C(p).

UR - http://www.scopus.com/inward/record.url?scp=0033017136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033017136&partnerID=8YFLogxK

M3 - Article

VL - 27

SP - 701

EP - 709

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 6

ER -